Division of Endocrinology, Metabolism & Molecular Medicine, Charles Drew University of Medicine & Sciences, UCLA School of Medicine, 1731 E 120th St, Los Angeles, CA 90059, USA.
Diabetologia. 2011 Feb;54(2):440-50. doi: 10.1007/s00125-010-1956-9. Epub 2010 Nov 4.
AIMS/HYPOTHESIS: Tissue-specific amplification of glucocorticoid action through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) affects the development of the metabolic syndrome. Hexose-6-phosphate dehydrogenase (H6PDH) mediates intracellular NADPH availability for 11β-HSD1 and depends on the glucose-6-phosphate transporter (G6PT). Little is known about the tissue-specific alterations of H6PDH and G6PT and their contributions to local glucocorticoid action in db/db mice.
We characterised the role of H6PDH and G6PT in pre-receptor metabolism of glucocorticoids by examining the production of the hepatic 11β-HSD1-H6PDH-G6PT system in db/db mice.
We observed that increased production of hepatic H6PDH in db/db mice was paralleled by upregulation of hepatic G6PT production and responded to elevated circulating levels of corticosterone. Treatment of db/db mice with the glucocorticoid antagonist RU486 markedly reduced production of both H6PDH and 11β-HSD1 and improved hyperglycaemia and insulin resistance. The reduction of H6PDH and 11β-HSD1 production by RU486 was accompanied by RU486-induced suppression of hepatic G6pt (also known as Slc37a4) mRNA. Incubation of mouse primary hepatocytes with corticosterone enhanced G6PT and H6PDH production with corresponding activation of 11β-HSD1 and PEPCK: effects that were blocked by RU486. Knockdown of H6pd by small interfering RNA showed effects comparable with those of RU486 for attenuating the corticosterone-induced H6PDH production and 11ß-HSD1 reductase activity in these intact cells. Addition of the G6PT inhibitor chlorogenic acid to primary hepatocytes suppressed H6PDH production.
CONCLUSIONS/INTERPRETATION: These findings suggest that increased hepatic H6PDH and G6PT production contribute to 11β-HSD1 upregulation of local glucocorticoid action that may be related to the development of type 2 diabetes.
目的/假设:通过 11β-羟类固醇脱氢酶 1 型(11β-HSD1)实现糖皮质激素作用的组织特异性放大会影响代谢综合征的发展。己糖-6-磷酸脱氢酶(H6PDH)介导细胞内 NADPH 对 11β-HSD1 的可用性,并且依赖于葡萄糖-6-磷酸转运蛋白(G6PT)。关于 H6PDH 和 G6PT 的组织特异性改变及其对 db/db 小鼠局部糖皮质激素作用的贡献,人们知之甚少。
我们通过检查 db/db 小鼠中肝 11β-HSD1-H6PDH-G6PT 系统的产生,研究了 H6PDH 和 G6PT 在糖皮质激素前受体代谢中的作用。
我们观察到,db/db 小鼠中肝 H6PDH 的产生增加与肝 G6PT 产生的上调相平行,并对循环中皮质酮水平的升高做出反应。用糖皮质激素拮抗剂 RU486 治疗 db/db 小鼠可显著降低 H6PDH 和 11β-HSD1 的产生,并改善高血糖和胰岛素抵抗。RU486 降低 H6PDH 和 11β-HSD1 的产生伴随着 RU486 诱导的肝 G6pt(也称为 Slc37a4)mRNA 的抑制。用皮质酮孵育小鼠原代肝细胞可增强 G6PT 和 H6PDH 的产生,同时激活 11β-HSD1 和 PEPCK:这些作用可被 RU486 阻断。用小干扰 RNA 敲低 H6pd 可减弱皮质酮诱导的这些完整细胞中 H6PDH 的产生和 11β-HSD1 还原酶活性,其效果与 RU486 相当。将 G6PT 抑制剂绿原酸添加到原代肝细胞中可抑制 H6PDH 的产生。
结论/解释:这些发现表明,肝 H6PDH 和 G6PT 产生的增加有助于局部糖皮质激素作用的 11β-HSD1 上调,这可能与 2 型糖尿病的发展有关。